Bayer’s Stivarga First Drug To Enter Brain Cancer Platform Trial
GBM AGILE is the first global adaptive clinical trial platform for glioblastoma and the German group's liver and colorectal cancer drug will be the first of several therapies to be studied.
You may also be interested in...
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.